Best practices for bioinformatic characterization of neoantigens for clinical utility
Open accessThe DOI matches its Crossref record; 207 of the 207 references it cites were found in a registry or an index.
Abstract
Neoantigens are newly formed peptides created from somatic mutations that are capable of inducing tumor-specific T cell recognition. Recently, researchers and clinicians have leveraged next generation sequencing technologies to identify neoantigens and to create personalized immunotherapies for cancer treatment. To create a personalized cancer vaccine, neoantigens must be computationally predicted from matched tumor-normal sequencing data, and then ranked according to their predicted capability in stimulating a T cell response. This candidate neoantigen prediction process involves multiple steps, including somatic mutation identification, HLA typing, peptide processing, and peptide-MHC binding prediction. The general workflow has been utilized for many preclinical and clinical trials, but there is no current consensus approach and few established best practices. In this article, we review recent discoveries, summarize the available computational tools, and provide analysis considerations for each step, including neoantigen prediction, prioritization, delivery, and validation methods. In addition to reviewing the current state of neoantigen analysis, we provide practical guidance, specific recommendations, and extensive discussion of critical concepts and points of confusion in the practice of neoantigen characterization for clinical use. Finally, we outline necessary areas of development, including the need to improve HLA class II typing accuracy, to expand software support for diverse neoantigen sources, and to incorporate clinical response data to improve neoantigen prediction algorithms. The ultimate goal of neoantigen characterization workflows is to create personalized vaccines that improve patient outcomes in diverse cancer types.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fast and accurate short read alignment with Burrows-Wheeler transform
Li, H., & Durbin, R. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp324 · Cited by 58,607
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625 · cited 1×
“Immune cell profiling CIBERSORT [152], TIMER [153], quanTIseq [200], immunophenogram [201], MCPcounter [202], SSGSEA [203]”
MethodSTAR: ultrafast universal RNA-seq aligner
Dobin, A., Davis, C. A., Schlesinger, F., Drenkow, J., Zaleski, C., Jha, S., Batut, P., Chaisson, M., & Gingeras, T. R. (2013) · Bioinformatics · doi:10.1093/bioinformatics/bts635 · Cited by 51,709
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
HISAT: a fast spliced aligner with low memory requirements
Kim, D., Langmead, B., & Salzberg, S. L. (2015) · Nature Methods · doi:10.1038/nmeth.3317 · Cited by 24,112 · cited 1×
“Alignment DNA: Bwa-mem [161] RNA: STAR [162], HISAT2 [163]”
StringTie enables improved reconstruction of a transcriptome from RNA-seq reads
Pertea, M., Pertea, G. M., Antonescu, C. M., Chang, T.-C., Mendell, J. T., & Salzberg, S. L. (2015) · Nature Biotechnology · doi:10.1038/nbt.3122 · Cited by 14,298 · cited 1×
“Gene or transcript abundance estimation StringTie [173], Kallisto [174]”
BackgroundRobust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224 · cited 1×
“Methods such as CIBERSORT have been developed to characterize cell compositions on the basis of gene expression profiles from tumor samples [152].”
MethodNear-optimal probabilistic RNA-seq quantification
Bray, N. L., Pimentel, H., Melsted, P., & Pachter, L. (2016) · Nature Biotechnology · doi:10.1038/nbt.3519 · Cited by 9,723
Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration
Thorvaldsdottir, H., Robinson, J. T., & Mesirov, J. P. (2013) · Briefings in Bioinformatics · doi:10.1093/bib/bbs017 · Cited by 9,049 · cited 1×
“Regardless of the combination of callers used, manual review of matched tumor – normal samples in Integrative Genomics Viewer (IGV) [26], with a documented standard operating procedure, is recommended to further reduce false positives [27].”
MethodMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
Li, T., Fan, J., Wang, B., Traugh, N., Chen, Q., Liu, J. S., Li, B., & Liu, X. S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0307 · Cited by 5,913 · cited 1×
“Association between immune cell infiltrates and various factors, including somatic mutation, copy number variation, and gene expression, can be explored interactively through TIMER [153].”
BackgroundCharoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981 · cited 1×
“MuTect2 [19] and Strelka [20] have high sensitivity in detecting SNVs at low allele fractions, enabling accurate sub-clonal variant detection.”
VarScan 2: Somatic mutation and copy number alteration discovery in cancer by exome sequencing
Koboldt, D. C., Zhang, Q., Larson, D. E., Shen, D., McLellan, M. D., Lin, L., Miller, C. A., Mardis, E. R., Ding, L., & Wilson, R. K. (2012) · Genome Research · doi:10.1101/gr.129684.111 · Cited by 4,905 · cited 1×
“VarScan2 [21] and SomaticSniper [22] require higher allele fractions for recognizing variants but can improve performance in cases of tumor in normal contamination [23, 24].”
BackgroundComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Becht, E., Giraldo, N. A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F., Selves, J., Laurent-Puig, P., Sautès-Fridman, C., Fridman, W. H., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1070-5 · Cited by 3,685 · cited 1×
“Immune cell profiling CIBERSORT [152], TIMER [153], quanTIseq [200], immunophenogram [201], MCPcounter [202], SSGSEA [203]”
MethodAn immunogenic personal neoantigen vaccine for patients with melanoma
Ott, P. A., Hu, Z., Keskin, D. B., Shukla, S. A., Sun, J., Bozym, D. J., Zhang, W., Luoma, A., Giobbie-Hurder, A., Peter, L., et al. (2017) · Nature · doi:10.1038/nature22991 · Cited by 2,936 · cited 2×
“Synthetic long peptides (SLPs) are an effective neoantigen delivery mechanism in personalized immunotherapy pre-clinical studies and clinical trials [30, 101, 130, 131].”
BackgroundGenomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839 · cited 1×
“Studies have shown that, in addition to tumor mutational burden (TMB), high neoantigen burden can be a predictor of response to immune checkpoint blockade (ICB) therapy [6, 7].”
BackgroundA survey of best practices for RNA-seq data analysis
Conesa, A., Madrigal, P., Tarazona, S., Gomez-Cabrero, D., Cervera, A., McPherson, A., Szcześniak, M. W., Gaffney, D. J., Elo, L. L., Zhang, X., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-0881-8 · Cited by 2,794 · cited 1×
“All interpretation of RNA-seq should be accompanied by comprehensive QC analysis of the data [204].”
MethodRSeQC: quality control of RNA-seq experiments
Wang, L., Wang, S., & Li, W. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts356 · Cited by 2,788 · cited 1×
“com/s-andrews/FastQC), RSeQC [164], MultiQC (https://github.”
The Mutational Landscape of Head and Neck Squamous Cell Carcinoma
Stransky, N., Egloff, A. M., Tward, A. D., Kostic, A. D., Cibulskis, K., Sivachenko, A., Kryukov, G. V., Lawrence, M. S., Sougnez, C., McKenna, A., et al. (2011) · Science · doi:10.1126/science.1208130 · Cited by 2,504
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488 · cited 2×
“Recently, neoantigen vaccine trials for melanoma demonstrated that SNV-derived neoantigens can expand T cell populations [28] and induce disease regression [29, 30].”
Background(2015) · doi:10.1093/bioinformatics/btv710 · Cited by 2,234 · cited 1×
“Variant callers SNV/Indel: Mutect [19], Strelka [20], VarScan2 [21], SomaticSniper [22], Shimmer [165], VarDict [166], deepSNV [167], EBCall [40] Structural variants: Pindel [43], Manta [168], Lumpy [169] Fusions: STAR-Fusion [48], Pizzly [47], SOAPfuse [170], JAFFA [49], ChimPipe [171], GFusion [50], INTEGRATE [51]”
BackgroundThe Immune Epitope Database (IEDB): 2018 update
Vita, R., Mahajan, S., Overton, J. A., Dhanda, S. K., Martini, S., Cantrell, J. R., Wheeler, D. K., Sette, A., & Peters, B. (2019) · Nucleic Acids Research · doi:10.1093/nar/gky1006 · Cited by 2,186 · cited 2×
“To address the entirety of this process, the Immune Epitope Database (IEDB) has also developed a predictor for the combination of these processes (proteasomal cleavage/ TAP transport/MHC class I) [90, 96].”
BackgroundMethodYe, K., Schulz, M. H., Long, Q., Apweiler, R., & Ning, Z. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp394 · Cited by 2,022 · cited 1×
“Pindel [43] specializes in calling larger indels, from 0.50 – 10 kilobases in length, and structural variants.”
BackgroundInfluentialThe IPD and IMGT/HLA database: allele variant databases
Robinson, J., Halliwell, J. A., Hayhurst, J. D., Flicek, P., Parham, P., & Marsh, S. G. E. (2015) · Nucleic Acids Research · doi:10.1093/nar/gku1161 · Cited by 1,740 · cited 1×
“This locus is highly polymorphic, with over 12,000 established alleles and more in discovery [64].”
BackgroundMiXCR: software for comprehensive adaptive immunity profiling
Bolotin, D. A., Poslavsky, S., Mitrophanov, I., Shugay, M., Mamedov, I. Z., Putintseva, E. V., & Chudakov, D. M. (2015) · Nature Methods · doi:10.1038/nmeth.3364 · Cited by 1,722 · cited 1×
“MixCR has been used for TCR alignment and assembly in both bulk and single-cell methods [144, 147].”
MethodCancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer
Tran, E., Turcotte, S., Gros, A., Robbins, P. F., Lu, Y.-C., Dudley, M. E., Wunderlich, J. R., Somerville, R. P., Hogan, K., Hinrichs, C. S., et al. (2014) · Science · doi:10.1126/science.1251102 · Cited by 1,718
Strelka: accurate somatic small-variant calling from sequenced tumor–normal sample pairs
Saunders, C. T., Wong, W. S. W., Swamy, S., Becq, J., Murray, L. J., & Cheetham, R. K. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts271 · Cited by 1,635 · cited 1×
“MuTect2 [19] and Strelka [20] have high sensitivity in detecting SNVs at low allele fractions, enabling accurate sub-clonal variant detection.”
BackgroundLUMPY: a probabilistic framework for structural variant discovery
Layer, R. M., Chiang, C., Quinlan, A. R., & Hall, I. M. (2014) · Genome Biology · doi:10.1186/gb-2014-15-6-r84 · Cited by 1,554 · cited 1×
“Variant callers SNV/Indel: Mutect [19], Strelka [20], VarScan2 [21], SomaticSniper [22], Shimmer [165], VarDict [166], deepSNV [167], EBCall [40] Structural variants: Pindel [43], Manta [168], Lumpy [169] Fusions: STAR-Fusion [48], Pizzly [47], SOAPfuse [170], JAFFA [49], ChimPipe [171], GFusion [50], INTEGRATE [51]”
BackgroundPathways of Antigen Processing
Blum, J. S., Wearsch, P. A., & Cresswell, P. (2013) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032712-095910 · Cited by 1,547 · cited 2×
“Here, peptides can bind to class II molecules and are protected from destructive processing [97, 98].”
BackgroundFinotello, F., Mayer, C., Plattner, C., Laschober, G., Rieder, D., Hackl, H., Krogsdam, A., Loncova, Z., Posch, W., Wilflingseder, D., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0638-6 · Cited by 1,542 · cited 1×
“Immune cell profiling CIBERSORT [152], TIMER [153], quanTIseq [200], immunophenogram [201], MCPcounter [202], SSGSEA [203]”
MethodJurtz, V., Paul, S., Andreatta, M., Marcatili, P., Peters, B., & Nielsen, M. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1700893 · Cited by 1,470 · cited 7×
“Most of the attention in the field has been focused on predicting the binding affinity between the patient’s MHC molecule and a given peptide sequence, as this is believed to provide much of the specificity of the overall recognition [87].”
BackgroundMethodInfluentialNeoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Keskin, D. B., Anandappa, A. J., Sun, J., Tirosh, I., Mathewson, N. D., Li, S., Oliveira, G., Giobbie-Hurder, A., Felt, K., Gjini, E., et al. (2019) · Nature · doi:10.1038/s41586-018-0792-9 · Cited by 1,432 · cited 1×
“Synthetic long peptides (SLPs) are an effective neoantigen delivery mechanism in personalized immunotherapy pre-clinical studies and clinical trials [30, 101, 130, 131].”
BackgroundT-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368 · cited 1×
“Studies have identified oligoclonal T cell populations that converge, with consistent CDR3 motif sequences, to recognize the same neoantigen [150].”
BackgroundAllele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.001 · Cited by 1,298 · cited 1×
“Another tool, LOHHLA, can identify copy number variations in the HLA locus that result in loss of heterozygosity [81].”
MethodA dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
Carreno, B. M., Magrini, V., Becker-Hapak, M., Kaabinejadian, S., Hundal, J., Petti, A. A., Ly, A., Lie, W.-R., Hildebrand, W. H., Mardis, E. R., et al. (2015) · Science · doi:10.1126/science.aaa3828 · Cited by 1,285
Mutant MHC class II epitopes drive therapeutic immune responses to cancer
Kreiter, S., Vormehr, M., van de Roemer, N., Diken, M., Löwer, M., Diekmann, J., Boegel, S., Schrörs, B., Vascotto, F., Castle, J. C., et al. (2015) · Nature · doi:10.1038/nature14426 · Cited by 1,243 · cited 2×
“Synthetic long peptides (SLPs) are an effective neoantigen delivery mechanism in personalized immunotherapy pre-clinical studies and clinical trials [30, 101, 130, 131].”
BackgroundPersonalized vaccines for cancer immunotherapy
Sahin, U., & Türeci, Ö. (2018) · Science · doi:10.1126/science.aar7112 · Cited by 1,147 · cited 2×
“Multiple delivery mechanisms exist for use in clinical trials; these include synthetic peptides, DNA, mRNA, viral vectors, and ex-vivo-loaded dendritic cell vaccines [126, 127].”
BackgroundVaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia
Kenter, G. G., Welters, M. J. P., Valentijn, A. R. P. M., Lowik, M. J. G., Berends-van der Meer, D. M. A., Vloon, A. P. G., Essahsah, F., Fathers, L. M., Offringa, R., Drijfhout, J. W., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810097 · Cited by 1,102
Gapped sequence alignment using artificial neural networks: application to the MHC class I system
Andreatta, M., & Nielsen, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btv639 · Cited by 1,087 · cited 1×
“However, recently published or updated predictors almost exclusively employ variations of neural networks [87, 102, 104, 114], as shown in Table 3.”
BackgroundRobbins, P. F., Lu, Y.-C., El-Gamil, M., Li, Y. F., Gross, C., Gartner, J., Lin, J. C., Teer, J. K., Cliften, P., Tycksen, E., et al. (2013) · Nature Medicine · doi:10.1038/nm.3161 · Cited by 1,072
Identifying specificity groups in the T cell receptor repertoire
Glanville, J., Huang, H., Nau, A., Hatton, O., Wagar, L. E., Rubelt, F., Ji, X., Han, A., Krams, S. M., Pettus, C., et al. (2017) · Nature · doi:10.1038/nature22976 · Cited by 1,026 · cited 1×
“Oligoclo-nal events and the convergence of the T cell repertoire can be better studied with tools such as GLIPH, which was developed to identify consistent CDR3 motifs across [151] T cells in bulk TCR sequencing.”
MethodVarDict: a novel and versatile variant caller for next-generation sequencing in cancer research
Lai, Z., Markovets, A., Ahdesmaki, M., Chapman, B., Hofmann, O., McEwen, R., Johnson, J., Dougherty, B., Barrett, J. C., & Dry, J. R. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkw227 · Cited by 970 · cited 1×
“Variant callers SNV/Indel: Mutect [19], Strelka [20], VarScan2 [21], SomaticSniper [22], Shimmer [165], VarDict [166], deepSNV [167], EBCall [40] Structural variants: Pindel [43], Manta [168], Lumpy [169] Fusions: STAR-Fusion [48], Pizzly [47], SOAPfuse [170], JAFFA [49], ChimPipe [171], GFusion [50], INTEGRATE [51]”
BackgroundProperties of MHC Class I Presented Peptides That Enhance Immunogenicity
Calis, J. J. A., Maybeno, M., Greenbaum, J. A., Weiskopf, D., De Silva, A. D., Sette, A., Keşmir, C., & Peters, B. (2013) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1003266 · Cited by 923 · cited 1×
“This insufficiency probably results from the influence of other factors including the preprocessing of peptides, the stability of the pMHC complex [106, 107], and peptide immunogenicity [108].”
BackgroundTurajlic, S., Litchfield, K., Xu, H., Rosenthal, R., McGranahan, N., Reading, J. L., Wong, Y. N. S., Rowan, A., Kanu, N., Al Bakir, M., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30516-8 · Cited by 911 · cited 3×
“A pan-cancer analysis of 19 cancer types from The Cancer Genome Atlas demonstrated that frameshift-derived neoantigens were present in every cancer type [31].”
BackgroundInfluentialQuantifiable predictive features define epitope-specific T cell receptor repertoires
Dash, P., Fiore-Gartland, A. J., Hertz, T., Wang, G. C., Sharma, S., Souquette, A., Crawford, J. C., Clemens, E. B., Nguyen, T. H. O., Kedzierska, K., et al. (2017) · Nature · doi:10.1038/nature22383 · Cited by 897 · cited 1×
“Researchers have started to quantify these predictive features with the hope of modeling epitope – TCR specificity [160].”
BackgroundComprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients
Kahles, A., Lehmann, K.-V., Toussaint, N. C., Hüser, M., Stark, S. G., Sachsenberg, T., Stegle, O., Kohlbacher, O., Sander, C., Caesar-Johnson, S. J., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.07.001 · Cited by 897 · cited 2×
“…SNVs, including short insertions and deletions (indels) [31], fusions [32, 33], intron retentions [34], non-coding expressed regions [35], exon – exon junction epitopes [36], B cell receptor (BCR) and T cell receptor (TCR) sequences for B and T cell malignancies, respectively [37], and more [38].”
BackgroundProPred: prediction of HLA-DR binding sites
Singh, H., & Raghava, G. P. S. (2001) · Bioinformatics · doi:10.1093/bioinformatics/17.12.1236 · Cited by 841 · cited 1×
“MHC binding predictors Class I predictors: SMM [111], SMMPMBEC [112], Pickpocket [113], NetMHC [114], NetMHCpan [87], NetMHCcons [180], MHCflurry [102], MHCnuggets [181], MHCSeqNet [103], EDGE [104] Class II predictors: SMMAlign [111], NNAlign [182], ProPred [183], NetMHCII(2.”
Methodvan Rooij, N., van Buuren, M. M., Philips, D., Velds, A., Toebes, M., Heemskerk, B., van Dijk, L. J. A., Behjati, S., Hilkmann, H., el Atmioui, D., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.47.7521 · Cited by 798
Improved methods for predicting peptide binding affinity to MHC class II molecules
Jensen, K. K., Andreatta, M., Marcatili, P., Buus, S., Greenbaum, J. A., Yan, Z., Sette, A., Peters, B., & Nielsen, M. (2018) · Immunology · doi:10.1111/imm.12889 · Cited by 794 · cited 1×
“A selection of popular MHC class II binding prediction algorithms are summarized in Table 1 [116].”
MethodGettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., Wurtz, A., Dong, W., Cai, G., Melnick, M. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0593 · Cited by 787 · cited 1×
“In lung cancer and MSI-CRC, mutations or biallelic loss of B2M causes lack of class I HLA presentation [82, 83].”
BackgroundOptiType: precision HLA typing from next-generation sequencing data
Szolek, A., Schubert, B., Mohr, C., Sturm, M., Feldhahn, M., & Kohlbacher, O. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu548 · Cited by 769 · cited 1×
“Although many class I typing algorithms exist, OptiType [69], Polysolver [70], and PHLAT [71] currently have the highest reported accuracies [67, 68, 70].”
BackgroundChicz, R. M., Urban, R. G., Lane, W. S., Gorga, J. C., Stern, L. J., Vignali, D. A. A., & Strominger, J. L. (1992) · Nature · doi:10.1038/358764a0 · Cited by 768 · cited 1×
“The most frequently observed lengths of peptides that bind to class II MHCs are between 13 and 25 amino acids [115], whereas those for class I typically fall between 8 and 15 amino acids [87].”
BackgroundSturniolo, T., Bono, E., Ding, J., Raddrizzani, L., Tuereci, O., Sahin, U., Braxenthaler, M., Gallazzi, F., Protti, M. P., Sinigaglia, F., et al. (1999) · Nature Biotechnology · doi:10.1038/9858 · Cited by 743 · cited 1×
“2) [116], TEPITOPE [184], TEPITOPEpan [185], RANKPEP [186], MultiRTA [187], OWA-PSSM [188]”
A vaccine targeting mutant IDH1 induces antitumour immunity
Schumacher, T., Bunse, L., Pusch, S., Sahm, F., Wiestler, B., Quandt, J., Menn, O., Osswald, M., Oezen, I., Ott, M., et al. (2014) · Nature · doi:10.1038/nature13387 · Cited by 706 · cited 1×
“Synthetic long peptides (SLPs) are an effective neoantigen delivery mechanism in personalized immunotherapy pre-clinical studies and clinical trials [30, 101, 130, 131].”
BackgroundLinnemann, C., van Buuren, M. M., Bies, L., Verdegaal, E. M. E., Schotte, R., Calis, J. J. A., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D. E., et al. (2015) · Nature Medicine · doi:10.1038/nm.3773 · Cited by 679
Comprehensive analysis of cancer-associated somatic mutations in class I HLA genes
Shukla, S. A., Rooney, M. S., Rajasagi, M., Tiao, G., Dixon, P. M., Lawrence, M. S., Stevens, J., Lane, W. J., Dellagatta, J. L., Steelman, S., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3344 · Cited by 675 · cited 3×
“Although many class I typing algorithms exist, OptiType [69], Polysolver [70], and PHLAT [71] currently have the highest reported accuracies [67, 68, 70].”
SomaticSniper: identification of somatic point mutations in whole genome sequencing data
Larson, D. E., Harris, C. C., Chen, K., Koboldt, D. C., Abbott, T. E., Dooling, D. J., Ley, T. J., Mardis, E. R., Wilson, R. K., & Ding, L. (2012) · Bioinformatics · doi:10.1093/bioinformatics/btr665 · Cited by 661 · cited 1×
“VarScan2 [21] and SomaticSniper [22] require higher allele fractions for recognizing variants but can improve performance in cases of tumor in normal contamination [23, 24].”
BackgroundAbelin, J. G., Keskin, D. B., Sarkizova, S., Hartigan, C. R., Zhang, W., Sidney, J., Stevens, J., Lane, W., Zhang, G. L., Eisenhaure, T. M., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.02.007 · Cited by 617 · cited 1×
“However, continuous development in MS profiling techniques [109] may soon close the gap between the two types of data.”
BackgroundVDJtools: Unifying Post-analysis of T Cell Receptor Repertoires
Shugay, M., Bagaev, D. V., Turchaninova, M. A., Bolotin, D. A., Britanova, O. V., Putintseva, E. V., Pogorelyy, M. V., Nazarov, V. I., Zvyagin, I. V., Kirgizova, V. I., et al. (2015) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1004503 · Cited by 614 · cited 1×
“TCR repertoire profiling LymAnalyzer [194], MiXCR [147], MIGEC [148], pRESTO [195], TRUST [196], TraCeR [145], VDJtools [197], VDJviz [198], ImmunoSEQ [199], GLIPH [151]”
MethodTumor neoantigens: building a framework for personalized cancer immunotherapy
Gubin, M. M., Artyomov, M. N., Mardis, E. R., & Schreiber, R. D. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80008 · Cited by 613 · cited 1×
“The general concept of neoantigens and their role in personalized immunotherapies have been extensively reviewed elsewhere [10 – 12].”
BackgroundImmunotherapy of established (pre)malignant disease by synthetic long peptide vaccines
Melief, C. J. M., & van der Burg, S. H. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2373 · Cited by 594
Nielsen, M., Lundegaard, C., & Lund, O. (2007) · BMC Bioinformatics · doi:10.1186/1471-2105-8-238 · Cited by 594 · cited 1×
“Initially, predictors relied on linear regression algorithms and more specifically on stabilized matrix methods, such as SMM [111], SMMPMBEC [112], and Pickpocket [113].”
The anticancer immune response: indispensable for therapeutic success?
Zitvogel, L., Apetoh, L., Ghiringhelli, F., André, F., Tesniere, A., & Kroemer, G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35180 · Cited by 573 · cited 1×
“The adaptive immune system has inherent antitumor properties that are capable of inducing tumor-specific cell death [1, 2].”
BackgroundLeone, P., Shin, E.-C., Perosa, F., Vacca, A., Dammacco, F., & Racanelli, V. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt184 · Cited by 553 · cited 1×
“Downregulation of B2M , TAP1 , and TAP2 expression has also been shown to inhibit tumor antigen presentation [84, 85] and correlate with metastatic breast cancer phenotypes [86].”
BackgroundGenetic Mechanisms of Immune Evasion in Colorectal Cancer
Grasso, C. S., Giannakis, M., Wells, D. K., Hamada, T., Mu, X. J., Quist, M., Nowak, J. A., Nishihara, R., Qian, Z. R., Inamura, K., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1327 · Cited by 535 · cited 1×
“In lung cancer and MSI-CRC, mutations or biallelic loss of B2M causes lack of class I HLA presentation [82, 83].”
BackgroundNoncoding regions are the main source of targetable tumor-specific antigens
Laumont, C. M., Vincent, K., Hesnard, L., Audemard, É., Bonneil, É., Laverdure, J.-P., Gendron, P., Courcelles, M., Hardy, M.-P., Côté, C., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aau5516 · Cited by 535 · cited 2×
“…beyond simple SNVs, including short insertions and deletions (indels) [31], fusions [32, 33], intron retentions [34], non-coding expressed regions [35], exon – exon junction epitopes [36], B cell receptor (BCR) and T cell receptor (TCR) sequences for B and T cell malignancies, respectively [37],…”
BackgroundNielsen, M., Lundegaard, C., Lund, O., & Keşmir, C. (2005) · Immunogenetics · doi:10.1007/s00251-005-0781-7 · Cited by 491 · cited 2×
“These tools include NetChop20S [89], NetChopCterm [89], and ProteaSMM [89, 90] for MHC class I antigens, and the more recent PepCleaveCD4 and MHC NP II for MHC class II antigens [91, 92].”
MethodVander Heiden, J. A., Yaari, G., Uduman, M., Stern, J. N. H., O’Connor, K. C., Hafler, D. A., Vigneault, F., & Kleinstein, S. H. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu138 · Cited by 465 · cited 1×
“TCR repertoire profiling LymAnalyzer [194], MiXCR [147], MIGEC [148], pRESTO [195], TRUST [196], TraCeR [145], VDJtools [197], VDJviz [198], ImmunoSEQ [199], GLIPH [151]”
MethodThe response of autologous T cells to a human melanoma is dominated by mutated neoantigens
Lennerz, V., Fatho, M., Gentilini, C., Frye, R. A., Lifke, A., Ferel, D., Wölfel, C., Huber, C., & Wölfel, T. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0500090102 · Cited by 456 · cited 1×
“Neoantigens are specifically defined here as peptides derived from somatic mutations that provide an avenue for tumor-specific immune cell recognition and that are important targets for cancer immuno-therapies [3 – 5].”
BackgroundT cell fate and clonality inference from single-cell transcriptomes
(2016) · doi:10.1038/nmeth.3800 · Cited by 434 · cited 18×
“The presence of many false positives makes accurate detection difficult, but this can be mitigated by using multiple tools [52] and by requiring predictions to be supported by multiple callers and/or data types (e.g., WGS and RNA-seq).”
MethodInfluentialTowards error-free profiling of immune repertoires
Shugay, M., Britanova, O. V., Merzlyak, E. M., Turchaninova, M. A., Mamedov, I. Z., Tuganbaev, T. R., Bolotin, D. A., Staroverov, D. B., Putintseva, E. V., Plevova, K., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2960 · Cited by 428 · cited 1×
“MIGEC [148] is utilized for methods involving the use of unique molecular identifiers, whereas TraCeR is designed specifically for single-cell methods [145].”
MethodMHCflurry: Open-Source Class I MHC Binding Affinity Prediction
O'Donnell, T. J., Rubinsteyn, A., Bonsack, M., Riemer, A. B., Laserson, U., & Hammerbacher, J. (2018) · Cell Systems · doi:10.1016/j.cels.2018.05.014 · Cited by 409
Quantifying tumor-infiltrating immune cells from transcriptomics data
Finotello, F., & Trajanoski, Z. (2018) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2150-z · Cited by 407 · cited 1×
“This topic has been reviewed in more depth elsewhere [154].”
BackgroundNetMHCcons: a consensus method for the major histocompatibility complex class I predictions
Karosiene, E., Lundegaard, C., Lund, O., & Nielsen, M. (2012) · Immunogenetics · doi:10.1007/s00251-011-0579-8 · Cited by 396
Duan, F., Duitama, J., Al Seesi, S., Ayres, C. M., Corcelli, S. A., Pawashe, A. P., Blanchard, T., McMahon, D., Sidney, J., Sette, A., et al. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20141308 · Cited by 378 · cited 2×
“…correspond to founding clones Variant types and agretopicity Calculation of ‘ agretopicity ’ (also known as ‘ differential agretopicity index ’ [121], or ‘ wild-type/mutant binding affinity fold change ’ ) refers to an attempt to estimate the degree to which a neoantigen ’ s ability to bind to…”
BackgroundPrediction of MHC class I binding peptides using profile motifs
Reche, P. A., Glutting, J.-P., & Reinherz, E. L. (2002) · Human Immunology · doi:10.1016/s0198-8859(02)00432-9 · Cited by 375 · cited 1×
“2) [116], TEPITOPE [184], TEPITOPEpan [185], RANKPEP [186], MultiRTA [187], OWA-PSSM [188]”
Isolation of neoantigen-specific T cells from tumor and peripheral lymphocytes
Cohen, C. J., Gartner, J. J., Horovitz-Fried, M., Shamalov, K., Trebska-McGowan, K., Bliskovsky, V. V., Parkhurst, M. R., Ankri, C., Prickett, T. D., Crystal, J. S., et al. (2015) · Journal of Clinical Investigation · doi:10.1172/jci82416 · Cited by 374 · cited 1×
“Standard methods such as IFN-γ ELISPOT assays [139] or MHC multimer assays [140] are beyond the scope of this review, but have been used widely for neoantigen validation purposes [28, 141].”
MethodImmunogenic neoantigens derived from gene fusions stimulate T cell responses
Yang, W., Lee, K.-W., Srivastava, R. M., Kuo, F., Krishna, C., Chowell, D., Makarov, V., Hoen, D., Dalin, M. G., Wexler, L., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0434-2 · Cited by 374 · cited 1×
“…also increased appreciation for diverse neoantigen sources beyond simple SNVs, including short insertions and deletions (indels) [31], fusions [32, 33], intron retentions [34], non-coding expressed regions [35], exon – exon junction epitopes [36], B cell receptor (BCR) and T cell receptor (TCR)…”
BackgroundWelters, M. J. P., Kenter, G. G., Piersma, S. J., Vloon, A. P. G., Löwik, M. J. G., Berends-van der Meer, D. M. A., Drijfhout, J. W., Valentijn, A. R. P. M., Wafelman, A. R., Oostendorp, J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1880 · Cited by 373
A large fraction of HLA class I ligands are proteasome-generated spliced peptides
Liepe, J., Marino, F., Sidney, J., Jeko, A., Bunting, D. E., Sette, A., Kloetzel, P. M., Stumpf, M. P. H., Heck, A. J. R., & Mishto, M. (2016) · Science · doi:10.1126/science.aaf4384 · Cited by 366 · cited 1×
“An additional orthogonal, but poorly supported, neoantigen source is the proteasome, which was found to be capable of creating novel antigens by splicing peptides from diverse proteins to create a single antigen [156].”
BackgroundAlternative tumour-specific antigens
Smith, C. C., Selitsky, S. R., Chai, S., Armistead, P. M., Vincent, B. G., & Serody, J. S. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0162-4 · Cited by 351 · cited 1×
“…SNVs, including short insertions and deletions (indels) [31], fusions [32, 33], intron retentions [34], non-coding expressed regions [35], exon – exon junction epitopes [36], B cell receptor (BCR) and T cell receptor (TCR) sequences for B and T cell malignancies, respectively [37], and more [38].”
BackgroundWarren, R. L., Freeman, J. D., Zeng, T., Choe, G., Munro, S., Moore, R., Webb, J. R., & Holt, R. A. (2011) · Genome Research · doi:10.1101/gr.115428.110 · Cited by 350 · cited 1×
“Studies have quantified or predicted the T cell richness, or total number of T cell clones, in the peripheral blood of a healthy individual as up to 10 19 cells [146].”
BackgroundTenzer, S., Peters, B., Bulik, S., Schoor, O., Lemmel, C., Schatz, M. M., Kloetzel, P.-M., Rammensee, H.-G., Schild, H., & Holzhütter, H.-G. (2005) · CMLS Cellular and Molecular Life Sciences · doi:10.1007/s00018-005-4528-2 · Cited by 349 · cited 2×
“To address the entirety of this process, the Immune Epitope Database (IEDB) has also developed a predictor for the combination of these processes (proteasomal cleavage/ TAP transport/MHC class I) [90, 96].”
MethodDesign and use of conditional MHC class I ligands
Toebes, M., Coccoris, M., Bins, A., Rodenko, B., Gomez, R., Nieuwkoop, N. J., van de Kasteele, W., Rimmelzwaan, G. F., Haanen, J. B. A. G., Ovaa, H., et al. (2006) · Nature Medicine · doi:10.1038/nm1360 · Cited by 347 · cited 1×
“Standard methods such as IFN-γ ELISPOT assays [139] or MHC multimer assays [140] are beyond the scope of this review, but have been used widely for neoantigen validation purposes [28, 141].”
MethodWong, Y.-H., Lee, T.-Y., Liang, H.-K., Huang, C.-M., Wang, T.-Y., Yang, Y.-H., Chu, C.-H., Huang, H.-D., Ko, M.-T., & Hwang, J.-K. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm322 · Cited by 343
Identifying MHC Class I Epitopes by Predicting the TAP Transport Efficiency of Epitope Precursors
Peters, B., Bulik, S., Tampe, R., van Endert, P. M., & Holzhütter, H.-G. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.4.1741 · Cited by 339 · cited 1×
“Different methods have been employed in an attempt to determine which peptides have high affinity for TAP binding, including simple/cascade support vector machine (SVM) models [93, 94] and weight matrix models [95].”
MethodAntigen receptor repertoire profiling from RNA-seq data
Bolotin, D. A., Poslavsky, S., Davydov, A. N., Frenkel, F. E., Fanchi, L., Zolotareva, O. I., Hemmers, S., Putintseva, E. V., Obraztsova, A. S., Shugay, M., et al. (2017) · Nature Biotechnology · doi:10.1038/nbt.3979 · Cited by 333 · cited 2×
“MixCR has been used for TCR alignment and assembly in both bulk and single-cell methods [144, 147].”
MethodIntron retention is a source of neoepitopes in cancer
Smart, A. C., Margolis, C. A., Pimentel, H., He, M. X., Miao, D., Adeegbe, D., Fugmann, T., Wong, K.-K., & Van Allen, E. M. (2018) · Nature Biotechnology · doi:10.1038/nbt.4239 · Cited by 322 · cited 1×
“…for diverse neoantigen sources beyond simple SNVs, including short insertions and deletions (indels) [31], fusions [32, 33], intron retentions [34], non-coding expressed regions [35], exon – exon junction epitopes [36], B cell receptor (BCR) and T cell receptor (TCR) sequences for B and T…”
BackgroundOverview of methodologies for T-cell receptor repertoire analysis
Rosati, E., Dowds, C. M., Liaskou, E., Henriksen, E. K. K., Karlsen, T. H., & Franke, A. (2017) · BMC Biotechnology · doi:10.1186/s12896-017-0379-9 · Cited by 322 · cited 1×
“Commercial services such as Adaptive, ClonTech, and iRepertoire differ in a number of aspects, including required starting material, their library preparation methods, the targeted TCR chains and/or CDR regions for sequencing, the supported organisms, and the sequencing platforms used [143].”
BackgroundLarsen, M. V., Lundegaard, C., Lamberth, K., Buus, S., Brunak, S., Lund, O., & Nielsen, M. (2005) · European Journal of Immunology · doi:10.1002/eji.200425811 · Cited by 313 · cited 1×
“Once the mutations are confirmed to exist and be expressed, the pipelines then generate a list of neoantigen candidates and consider the probability of cleavage, the location of cleavage, and the TAP transport efficiency of each candidate [8, 123, 124].”
BackgroundDeep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification
Bulik-Sullivan, B., Busby, J., Palmer, C. D., Davis, M. J., Murphy, T., Clark, A., Busby, M., Duke, F., Yang, A., Young, L., et al. (2019) · Nature Biotechnology · doi:10.1038/nbt.4313 · Cited by 307 · cited 3×
“Here, we describe the current state of the art with respect to algorithmic innovation and refinement of the major classes of data that are used to train these algorithms (largely from in vitro binding assays involving specific MHCs and peptide libraries or from MS-based approaches) [87, 102 – 104].”
BackgroundMethodLandscape of tumor-infiltrating T cell repertoire of human cancers
Li, B., Li, T., Pignon, J.-C., Wang, B., Wang, J., Shukla, S. A., Dou, R., Chen, Q., Hodi, F. S., Choueiri, T. K., et al. (2016) · Nature Genetics · doi:10.1038/ng.3581 · Cited by 306
pVACtools: A Computational Toolkit to Identify and Visualize Cancer Neoantigens
Hundal, J., Kiwala, S., McMichael, J., Miller, C. A., Xia, H., Wollam, A. T., Liu, C. J., Zhao, S., Feng, Y.-Y., Graubert, A. P., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0401 · Cited by 300
Self-citationSlingluff, C. L. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e318233e5b2 · Cited by 299 · cited 1×
“SLPs have greater efficacy than short synthetic peptides, of 8 – 11 amino acids, because longer peptides require internalization and processing by professional APCs, whereas short peptides can induce immunological tolerance by binding directly to MHC-I on non-professional APCs [132 – 134].”
BackgroundAcquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA
Paulson, K. G., Voillet, V., McAfee, M. S., Hunter, D. S., Wagener, F. D., Perdicchio, M., Valente, W. J., Koelle, S. J., Church, C. D., Vandeven, N., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06300-3 · Cited by 286 · cited 2×
“Recently, researchers have identified transcriptional HLA repression in a patient with Merkel cell carcinoma (MCC) following treatment with autologous T cell therapy and ICB [76].”
BackgroundSanghera, D. K., Ortega, L., Han, S., Singh, J., Ralhan, S. K., Wander, G. S., Mehra, N. K., Mulvihill, J. J., Ferrell, R. E., Nath, S. K., et al. (2008) · BMC Medical Genetics · doi:10.1186/1471-2350-9-59 · Cited by 285
STAR-Fusion: Fast and Accurate Fusion Transcript Detection from RNA-Seq
Haas, B. J., Dobin, A., Stransky, N., Li, B., Yang, X., Tickle, T., Bankapur, A., Ganote, C., Doak, T. G., Pochet, N., et al. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/120295 · Cited by 279 · cited 1×
“Many tools have been developed to predict fusion genes from RNA-seq and/or whole genome sequencing (WGS) data; recent tools include pizzly [47], STAR-fusion [48], JAFFA [49], GFusion [50], and INTEGRATE [51] (refer to Table 1).”
TepiTool: A Pipeline for Computational Prediction of T Cell Epitope Candidates
Paul, S., Sidney, J., Sette, A., & Peters, B. (2016) · Current Protocols in Immunology · doi:10.1002/cpim.12 · Cited by 274 · cited 8×
“This is reflected in some class II binding prediction tools, although it should be noted that the IEDB API and web resource currently enforce a length of 15 amino acids only”
MethodInfluentialHLA‐HD: An accurate HLA typing algorithm for next‐generation sequencing data
Kawaguchi, S., Higasa, K., Shimizu, M., Yamada, R., & Matsuda, F. (2017) · Human Mutation · doi:10.1002/humu.23230 · Cited by 273 · cited 1×
“Additional HLA typing algorithms, xHLA [74] and HLA-HD [75], have recently been published and show comparable accuracies to those of the tools described above.”
ResultVariations in MHC Class II Antigen Processing and Presentation in Health and Disease
Unanue, E. R., Turk, V., & Neefjes, J. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-041015-055420 · Cited by 270 · cited 1×
“Here, peptides can bind to class II molecules and are protected from destructive processing [97, 98].”
BackgroundHLA typing from RNA-Seq sequence reads
Boegel, S., Löwer, M., Schäfer, M., Bukur, T., de Graaf, J., Boisguérin, V., Türeci, Ö., Diken, M., Castle, J. C., & Sahin, U. (2012) · Genome Medicine · doi:10.1186/gm403 · Cited by 270 · cited 1×
“Few benchmarking studies that consider class II algo-rithm accuracy have been performed, but a combined class I and II comparison demonstrated that PHLAT [71], HLA-VBSeq [72], and seq2HLA [73] performed well with WES and RNA-seq data [67].”
MethodAntigen presentation profiling reveals recognition of lymphoma immunoglobulin neoantigens
Khodadoust, M. S., Olsson, N., Wagar, L. E., Haabeth, O. A. W., Chen, B., Swaminathan, K., Rawson, K., Liu, C. L., Steiner, D., Lund, P., et al. (2017) · Nature · doi:10.1038/nature21433 · Cited by 261 · cited 2×
“…SNVs, including short insertions and deletions (indels) [31], fusions [32, 33], intron retentions [34], non-coding expressed regions [35], exon – exon junction epitopes [36], B cell receptor (BCR) and T cell receptor (TCR) sequences for B and T cell malignancies, respectively [37], and more [38].”
BackgroundZhang, H., Lund, O., & Nielsen, M. (2009) · Bioinformatics · doi:10.1093/bioinformatics/btp137 · Cited by 255
Reliable detection of subclonal single-nucleotide variants in tumour cell populations
Gerstung, M., Beisel, C., Rechsteiner, M., Wild, P., Schraml, P., Moch, H., & Beerenwinkel, N. (2012) · Nature Communications · doi:10.1038/ncomms1814 · Cited by 246 · cited 1×
“Variant callers SNV/Indel: Mutect [19], Strelka [20], VarScan2 [21], SomaticSniper [22], Shimmer [165], VarDict [166], deepSNV [167], EBCall [40] Structural variants: Pindel [43], Manta [168], Lumpy [169] Fusions: STAR-Fusion [48], Pizzly [47], SOAPfuse [170], JAFFA [49], ChimPipe [171], GFusion [50], INTEGRATE [51]”
BackgroundXue, Y., Liu, Z., Cao, J., Ma, Q., Gao, X., Wang, Q., Jin, C., Zhou, Y., Wen, L., & Ren, J. (2011) · Protein Engineering Design and Selection · doi:10.1093/protein/gzq094 · Cited by 246 · cited 1×
“Several computational tools exist to predict post-translational modifications and alternative translation events from sequencing data, such as GPS [157] and KinasePhos [158] for phosphorylation events and altORFev [159] for alternative ORFs.”
MethodA review of somatic single nucleotide variant calling algorithms for next-generation sequencing data
Xu, C. (2018) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.01.003 · Cited by 242 · cited 1×
“Somatic variant callers identify single nucleotide variants (SNVs) from tumor and matched non-tumor DNA sequence data, such as whole genome, or more commonly, whole exome sequencing (WES) data [18].”
BackgroundSystematic Analysis of Splice-Site-Creating Mutations in Cancer
Jayasinghe, R. G., Cao, S., Gao, Q., Wendl, M. C., Vo, N. S., Reynolds, S. M., Zhao, Y., Climente-González, H., Chai, S., Wang, F., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.03.052 · Cited by 239 · cited 1×
“Tumor-specific splicing patterns can also cause distinct alternative 3 ′ or 5 ′ splice sites, known as splice-site-creating mutations, and these mutations are predicted to create an average of 2.0 – 2.5 neoantigens per mutation [55].”
BackgroundInfluentialRasmussen, M., Fenoy, E., Harndahl, M., Kristensen, A. B., Nielsen, I. K., Nielsen, M., & Buus, S. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600582 · Cited by 238 · cited 2×
“…pipelines also consider: (i) manufacturability by measuring peptide characteristics [9]; (ii) immunogenicity by comparing either self-antigens defined by the reference or by the wild-type proteome or known epitopes from viruses and bacteria provided by IEDB [119]; and (iii) pMHC stability [8, 107].”
BackgroundHopkins, A. C., Yarchoan, M., Durham, J. N., Yusko, E. C., Rytlewski, J. A., Robins, H. S., Laheru, D. A., Le, D. T., Lutz, E. R., & Jaffee, E. M. (2018) · JCI Insight · doi:10.1172/jci.insight.122092 · Cited by 233 · cited 1×
“Researchers have also established an association between the size and diversity of a patient ’ s TCR repertoire and their response to cancer immunotherapies [142].”
BackgroundBijker, M. S., van den Eeden, S. J. F., Franken, K. L., Melief, C. J. M., van der Burg, S. H., & Offringa, R. (2008) · European Journal of Immunology · doi:10.1002/eji.200737995 · Cited by 229 · cited 1×
“SLPs have greater efficacy than short synthetic peptides, of 8 – 11 amino acids, because longer peptides require internalization and processing by professional APCs, whereas short peptides can induce immunological tolerance by binding directly to MHC-I on non-professional APCs [132 – 134].”
BackgroundViral vector-based therapeutic cancer vaccines
Larocca, C., & Schlom, J. (2011) · The Cancer Journal · doi:10.1097/ppo.0b013e3182325e63 · Cited by 222 · cited 1×
“Adenovirus and vaccinia are the most common viral vectors for personalized vaccines; both are double-stranded DNA (dsDNA) viruses that can incorporate foreign DNA [137].”
BackgroundKim, Y., Sidney, J., Pinilla, C., Sette, A., & Peters, B. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-394 · Cited by 219 · cited 1×
“Initially, predictors relied on linear regression algorithms and more specifically on stabilized matrix methods, such as SMM [111], SMMPMBEC [112], and Pickpocket [113].”
MethodPeptide‐MHC class I stability is a better predictor than peptide affinity of CTL immunogenicity
Harndahl, M., Rasmussen, M., Roder, G., Dalgaard Pedersen, I., Sørensen, M., Nielsen, M., & Buus, S. (2012) · European Journal of Immunology · doi:10.1002/eji.201141774 · Cited by 217 · cited 1×
“This insufficiency probably results from the influence of other factors including the preprocessing of peptides, the stability of the pMHC complex [106, 107], and peptide immunogenicity [108].”
BackgroundApplications of Immunogenomics to Cancer
Liu, X. S., & Mardis, E. R. (2017) · Cell · doi:10.1016/j.cell.2017.01.014 · Cited by 205
MHC Class I–Associated Phosphopeptides Are the Targets of Memory-like Immunity in Leukemia
Cobbold, M., De La Peña, H., Norris, A., Polefrone, J. M., Qian, J., English, A. M., Cummings, K. L., Penny, S., Turner, J. E., Cottine, J., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3006061 · Cited by 204 · cited 1×
“Further, researchers have demonstrated that peptides with post translational modifications, including phosphorylation and O-GlcNAcylation, in primary leukemia samples can serve as MHC-I restricted neoanti-gens [57, 58].”
BackgroundSOAPfuse: an algorithm for identifying fusion transcripts from paired-end RNA-Seq data
Jia, W., Qiu, K., He, M., Song, P., Zhou, Q., Zhou, F., Yu, Y., Zhu, D., Nickerson, M. L., Wan, S., et al. (2013) · Genome Biology · doi:10.1186/gb-2013-14-2-r12 · Cited by 204 · cited 1×
“Variant callers SNV/Indel: Mutect [19], Strelka [20], VarScan2 [21], SomaticSniper [22], Shimmer [165], VarDict [166], deepSNV [167], EBCall [40] Structural variants: Pindel [43], Manta [168], Lumpy [169] Fusions: STAR-Fusion [48], Pizzly [47], SOAPfuse [170], JAFFA [49], ChimPipe [171], GFusion [50], INTEGRATE [51]”
BackgroundWang, R.-F., Johnston, S. L., Zeng, G., Topalian, S. L., Schwartzentruber, D. J., & Rosenberg, S. A. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.161.7.3596 · Cited by 204
MuPeXI: prediction of neo-epitopes from tumor sequencing data
Bjerregaard, A.-M., Nielsen, M., Hadrup, S. R., Szallasi, Z., & Eklund, A. C. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2001-3 · Cited by 204 · cited 9×
“These considerations include: the use of multiple binding prediction algorithms (variability among binding predictions); the integration of both DNA and RNA data (expression of neoantigen candidate genes or transcripts and expression of variant alleles); the phasing of variants (proximal variants detected on the same…”
BackgroundMethodInfluentialAn empirical Bayesian framework for somatic mutation detection from cancer genome sequencing data
Shiraishi, Y., Sato, Y., Chiba, K., Okuno, Y., Nagata, Y., Yoshida, K., Shiba, N., Hayashi, Y., Kume, H., Homma, Y., et al. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt126 · Cited by 200 · cited 1×
“For calling indels, in addition to Strelka, EBCall [40] demonstrates the least sensitivity to coverage variability [41, 42].”
MethodOptimizing Cancer Genome Sequencing and Analysis
Griffith, M., Miller, C. A., Griffith, O. L., Krysiak, K., Skidmore, Z. L., Ramu, A., Walker, J. R., Dang, H. X., Trani, L., Larson, D. E., et al. (2015) · Cell Systems · doi:10.1016/j.cels.2015.08.015 · Cited by 194
Self-citationDerivation of HLA types from shotgun sequence datasets
Warren, R. L., Choe, G., Freeman, D. J., Castellarin, M., Munro, S., Moore, R., & Holt, R. A. (2012) · Genome Medicine · doi:10.1186/gm396 · Cited by 192 · cited 1×
“HLA typing Class I: Optitype [69], Polysolver [70] Class I and II: Athlates [70, 175], HLAreporter [176], HLAminer [176, 177], HLAscan [72, 178], HLA-VBSeq [72], PHLAT [71], seq2HLA [73], xHLA [74]”
MethodHLA-Binding Properties of Tumor Neoepitopes in Humans
Fritsch, E. F., Rajasagi, M., Ott, P. A., Brusic, V., Hacohen, N., & Wu, C. J. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0227 · Cited by 190 · cited 1×
“Interpretation of agretopicity is primarily relevant when the mutant amino acid(s) involve anchor residues of the MHC [206] HLA naming conventions Neoantigen characterization workflows should consistently adopt the widely used standards and definitions for the communication of histocompatibility…”
Krøigård, A. B., Thomassen, M., Lænkholm, A.-V., Kruse, T. A., & Larsen, M. J. (2016) · PLOS ONE · doi:10.1371/journal.pone.0151664 · Cited by 180 · cited 1×
“For calling indels, in addition to Strelka, EBCall [40] demonstrates the least sensitivity to coverage variability [41, 42].”
MethodRobbe, P., Popitsch, N., Knight, S. J. L., Antoniou, P., Becq, J., He, M., Kanapin, A., Samsonova, A., Vavoulis, D. V., Ross, M. T., et al. (2018) · Genetics in Medicine · doi:10.1038/gim.2017.241 · Cited by 178
Analysis and prediction of affinity of TAP binding peptides using cascade SVM
Bhasin, M., & Raghava, G. P. S. (2004) · Protein Science · doi:10.1110/ps.03373104 · Cited by 178 · cited 1×
“Different methods have been employed in an attempt to determine which peptides have high affinity for TAP binding, including simple/cascade support vector machine (SVM) models [93, 94] and weight matrix models [95].”
MethodJAFFA: High sensitivity transcriptome-focused fusion gene detection
Davidson, N. M., Majewski, I. J., & Oshlack, A. (2015) · Genome Medicine · doi:10.1186/s13073-015-0167-x · Cited by 172 · cited 1×
“Many tools have been developed to predict fusion genes from RNA-seq and/or whole genome sequencing (WGS) data; recent tools include pizzly [47], STAR-fusion [48], JAFFA [49], GFusion [50], and INTEGRATE [51] (refer to Table 1).”
Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers
Wang, Q., Jia, P., Li, F., Chen, H., Ji, H., Hucks, D., Dahlman, K. B., Pao, W., & Zhao, Z. (2013) · Genome Medicine · doi:10.1186/gm495 · Cited by 170 · cited 1×
“VarScan2 [21] and SomaticSniper [22] require higher allele fractions for recognizing variants but can improve performance in cases of tumor in normal contamination [23, 24].”
BackgroundZhao, W., & Sher, X. (2018) · PLOS Computational Biology · doi:10.1371/journal.pcbi.1006457 · Cited by 168 · cited 3×
“The analysis also revealed that the incorporation of peptide elution data from MS experiments has indeed improved the accuracy of recent predictors when evaluated using high-quality naturally presented peptides [110].”
BackgroundNeoantigen Vaccine Delivery for Personalized Anticancer Immunotherapy
Guo, Y., Lei, K., & Tang, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01499 · Cited by 166 · cited 1×
“Multiple delivery mechanisms exist for use in clinical trials; these include synthetic peptides, DNA, mRNA, viral vectors, and ex-vivo-loaded dendritic cell vaccines [126, 127].”
BackgroundComparison of somatic mutation calling methods in amplicon and whole exome sequence data
Xu, H., DiCarlo, J., Satya, R. V., Peng, Q., & Wang, Y. (2014) · BMC Genomics · doi:10.1186/1471-2164-15-244 · Cited by 164 · cited 1×
“VarScan2 [21] and SomaticSniper [22] require higher allele fractions for recognizing variants but can improve performance in cases of tumor in normal contamination [23, 24].”
BackgroundLiu, S., Tsai, W.-H., Ding, Y., Chen, R., Fang, Z., Huo, Z., Kim, S., Ma, T., Chang, T.-Y., Priedigkeit, N. M., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1234 · Cited by 162 · cited 1×
“The presence of many false positives makes accurate detection difficult, but this can be mitigated by using multiple tools [52] and by requiring predictions to be supported by multiple callers and/or data types (e.g., WGS and RNA-seq).”
BackgroundUpdate on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different
Lee, C.-H., Yelensky, R., Jooss, K., & Chan, T. A. (2018) · Trends in Immunology · doi:10.1016/j.it.2018.04.005 · Cited by 162
Fast and accurate HLA typing from short-read next-generation sequence data with xHLA
Xie, C., Yeo, Z. X., Wong, M., Piper, J., Long, T., Kirkness, E. F., Biggs, W., Bloom, K., Spellman, S. R., Vierra‐Green, C., et al. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1707945114 · Cited by 158 · cited 2×
“…this may prevent correct prediction of the protein sequences of neoantigens Use of alternative contigs in the reference genome The inclusion or exclusion of alternative contigs from the latest human reference genome build can have important implications for HLA typing tools such as xHLA [74].”
BackgroundResultKim, S., Kim, H. S., Kim, E., Lee, M. G., Shin, E.-C., Paik, S., & Kim, S. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy022 · Cited by 158 · cited 1×
“Kim et al. [125] have attempted to capture the contributions of nine immunogenicity features through the training of machine-learning-based classifiers.”
BackgroundAn algorithm for the prediction of proteasomal cleavages
Kuttler, C., Nussbaum, A. K., Dick, T. P., Rammensee, H., Schild, H., & Hadeler, K.-P. (2000) · Journal of Molecular Biology · doi:10.1006/jmbi.2000.3683 · Cited by 155
Downregulation of MHC-I Expression Is Prevalent but Reversible in Merkel Cell Carcinoma
Paulson, K. G., Tegeder, A. R., Willmes, C., Iyer, J. G., Afanasiev, O. K., Schrama, D., Koba, S., Thibodeau, R. M., Nagase, K., Simonson, W. T., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0005 · Cited by 143 · cited 1×
“…found that the transcriptional silencing can be reversed in ex vivo cultures by treatment with 5-aza and other hypo-methylating agents, indicating that reversing the epigenetic silencing of the HLA genes could sensitize tumors that exhibit HLA downregulation in response to immuno-therapies [77].”
BackgroundRomero, J. M., Jiménez, P., Cabrera, T., Cózar, J. M., Pedrinaci, S., Tallada, M., Garrido, F., & Ruiz-Cabello, F. (2005) · International Journal of Cancer · doi:10.1002/ijc.20499 · Cited by 140 · cited 1×
“Downregulation of B2M, TAP1, and TAP2 expression has also been shown to inhibit tumor antigen presentation [84, 85] and correlate with metastatic breast cancer phenotypes [86].”
BackgroundIdentification of Glycopeptides as Posttranslationally Modified Neoantigens in Leukemia
Malaker, S. A., Penny, S. A., Steadman, L. G., Myers, P. T., Loke, J. C., Raghavan, M., Bai, D. L., Shabanowitz, J., Hunt, D. F., & Cobbold, M. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0280 · Cited by 140 · cited 1×
“Further, researchers have demonstrated that peptides with post translational modifications, including phosphorylation and O-GlcNAcylation, in primary leukemia samples can serve as MHC-I restricted neoanti-gens [57, 58].”
BackgroundNeoPredPipe: high-throughput neoantigen prediction and recognition potential pipeline
Schenck, R. O., Lakatos, E., Gatenbee, C., Graham, T. A., & Anderson, A. R. A. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2876-4 · Cited by 130 · cited 1×
“…(proximal variants detected on the same allele will influence neoantigen sequences) [32, 117]; the interpretation of variants in the context of clonality or heterogeneity [118]; the HLA expression and somatic mutations of patient tumors; and the prediction of tumor immunogenicity [119, 120].”
BackgroundNeoantigenic Potential of Complex Chromosomal Rearrangements in Mesothelioma
Mansfield, A. S., Peikert, T., Smadbeck, J. B., Udell, J. B. M., Garcia-Rivera, E., Elsbernd, L., Erskine, C. L., Van Keulen, V. P., Kosari, F., Murphy, S. J., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.001 · Cited by 129 · cited 1×
“The identification of novel sequences resulting from inter-and intrachromosomal rearrangements in mesothelioma also resulted in the prediction of multiple neoantigens for each patient [46].”
BackgroundINTEGRATE: gene fusion discovery using whole genome and transcriptome data
Zhang, J., White, N. M., Schmidt, H. K., Fulton, R. S., Tomlinson, C., Warren, W. C., Wilson, R. K., & Maher, C. A. (2016) · Genome Research · doi:10.1101/gr.186114.114 · Cited by 126 · cited 1×
“Many tools have been developed to predict fusion genes from RNA-seq and/or whole genome sequencing (WGS) data; recent tools include pizzly [47], STAR-fusion [48], JAFFA [49], GFusion [50], and INTEGRATE [51] (refer to Table 1).”
ATHLATES: accurate typing of human leukocyte antigen through exome sequencing
Liu, C., Yang, X., Duffy, B., Mohanakumar, T., Mitra, R. D., Zody, M. C., & Pfeifer, J. D. (2013) · Nucleic Acids Research · doi:10.1093/nar/gkt481 · Cited by 124 · cited 1×
“HLA typing Class I: Optitype [69], Polysolver [70] Class I and II: Athlates [70, 175], HLAreporter [176], HLAminer [176, 177], HLAscan [72, 178], HLA-VBSeq [72], PHLAT [71], seq2HLA [73], xHLA [74]”
MethodTEPITOPEpan: Extending TEPITOPE for Peptide Binding Prediction Covering over 700 HLA-DR Molecules
Zhang, L., Chen, Y., Wong, H., Zhou, S., Mamitsuka, H., & Zhu, S. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030483 · Cited by 119
Oh, E., Choi, Y., Kwon, M. J., Kim, R. N., Kim, Y. J., Song, J., Jung, K. S., & Shin, Y. K. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144162 · Cited by 115
INTEGRATE-neo: a pipeline for personalized gene fusion neoantigen discovery
Zhang, J., Mardis, E. R., & Maher, C. A. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btw674 · Cited by 113 · cited 4×
“Most pipe-lines currently take into account SNVs and indels, with only a subset considering gene fusion events [8, 32, 122].”
BackgroundMethodInfluentialThe neoepitope landscape in pediatric cancers
Chang, T., Carter, R. A., Li, Y., Li, Y., Wang, H., Edmonson, M. N., Chen, X. '., Arnold, P. Y., Geiger, T. L., Wu, G., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0468-3 · Cited by 112 · cited 3×
“Most pipelines currently take into account SNVs and indels, with only a subset considering gene fusion events [8, 32, 122].”
BackgroundMethodRonsin, C., Chung-Scott, V., Poullion, I., Aknouche, N., Gaudin, C., & Triebel, F. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.483 · Cited by 109 · cited 1×
“Alternative translation events resulting from non-AUG start codons and viral sequences that are associated with tumors (e.g., human papilloma virus (HPV)) are also a source of neoantigens [59 – 63].”
BackgroundMedler, T. R., Cotechini, T., & Coussens, L. M. (2015) · Trends in cancer · doi:10.1016/j.trecan.2015.07.008 · Cited by 109 · cited 1×
“The adaptive immune system has inherent antitumor properties that are capable of inducing tumor-specific cell death [1, 2].”
BackgroundDuperret, E. K., Perales-Puchalt, A., Stoltz, R., G.H., H., Mandloi, N., Barlow, J., Chaudhuri, A., Sardesai, N. Y., & Weiner, D. B. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0283 · Cited by 108
HLAscan: genotyping of the HLA region using next-generation sequencing data
Ka, S., Lee, S., Hong, J., Cho, Y., Sung, J., Kim, H.-N., Kim, H.-L., & Jung, J. (2017) · BMC Bioinformatics · doi:10.1186/s12859-017-1671-3 · Cited by 108
Barnell, E. K., Ronning, P., Campbell, K. M., Krysiak, K., Ainscough, B. J., Sheta, L. M., Pema, S. P., Schmidt, A. D., Richters, M. M., Cotto, K. C., et al. (2018) · Genetics in Medicine · doi:10.1038/s41436-018-0278-z · Cited by 107 · cited 2×
“…in-phase proximal variants, and other issues using a standard operating procedure for variant refinement, such as that outlined by Barnell et al. [27] Choosing RNA and DNA variant allele fraction (VAF) cutoffs It is impossible to define universal VAF recommendations because of the varying…”
MethodSelf-citationAn Efficient Single-Cell RNA-Seq Approach to Identify Neoantigen-Specific T Cell Receptors
Lu, Y.-C., Zheng, Z., Robbins, P. F., Tran, E., Prickett, T. D., Gartner, J. J., Li, Y. F., Ray, S., Franco, Z., Bliskovsky, V., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2017.10.018 · Cited by 103 · cited 1×
“[149] recently developed a single cell RNA-seq approach that identifies neoantigen-specific TCRs by culturing TILs with tandem minigene (TMG)-transfected or peptide-pulsed autologous APCs.”
BackgroundTIminer: NGS data mining pipeline for cancer immunology and immunotherapy
Tappeiner, E., Finotello, F., Charoentong, P., Mayer, C., Rieder, D., & Trajanoski, Z. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx377 · Cited by 101 · cited 1×
“…(proximal variants detected on the same allele will influence neoantigen sequences) [32, 117]; the interpretation of variants in the context of clonality or heterogeneity [118]; the HLA expression and somatic mutations of patient tumors; and the prediction of tumor immunogenicity [119, 120].”
BackgroundHLA-VBSeq: accurate HLA typing at full resolution from whole-genome sequencing data
Nariai, N., Kojima, K., Saito, S., Mimori, T., Sato, Y., Kawai, Y., Yamaguchi-Kabata, Y., Yasuda, J., & Nagasaki, M. (2015) · BMC Genomics · doi:10.1186/1471-2164-16-s2-s7 · Cited by 100 · cited 1×
“Few benchmarking studies that consider class II algo-rithm accuracy have been performed, but a combined class I and II comparison demonstrated that PHLAT [71], HLA-VBSeq [72], and seq2HLA [73] performed well with WES and RNA-seq data [67].”
MethodPolymorphism and evolution of HLA class I and II genes and molecules.
Little, A., & Parham, P. (1999) · PubMed · Cited by 99
FurinDB: A Database of 20-Residue Furin Cleavage Site Motifs, Substrates and Their Associated Drugs
Tian, S., Huang, Q., Fang, Y. R., & Wu, J. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12021060 · Cited by 98 · cited 1×
“Furin is a peptidase in the trans-Golgi network that cleaves immature proteins at sequence-specific motifs [138].”
BackgroundThe perfect personalized cancer therapy: cancer vaccines against neoantigens
Aurisicchio, L., Pallocca, M., Ciliberto, G., & Palombo, F. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0751-1 · Cited by 97 · cited 1×
“DNA vectors have also delivered neoantigens successfully in a recent preclinical study [135], and DNA neoantigen vaccine clinical trials are currently ongoing in pancreatic and triple-negative breast cancer [136].”
BackgroundHLAreporter: a tool for HLA typing from next generation sequencing data
Huang, Y., Yang, J., Ying, D., Zhang, Y., Shotelersuk, V., Hirankarn, N., Sham, P. C., Lau, Y., & Yang, W. (2015) · Genome Medicine · doi:10.1186/s13073-015-0145-3 · Cited by 86 · cited 1×
“HLA typing Class I: Optitype [69], Polysolver [70] Class I and II: Athlates [70, 175], HLAreporter [176], HLAminer [176, 177], HLAscan [72, 178], HLA-VBSeq [72], PHLAT [71], seq2HLA [73], xHLA [74]”
MethodKuijjer, M. L., Hogendoorn, P. C. W., & Cleton-Jansen, A.-M. (2013) · International Journal of Cancer · doi:10.1002/ijc.28124 · Cited by 83 · cited 1×
“Researchers recently investigated the presence of translocations in osteosarcoma, characterized by high genomic instability [44], and discovered multiple fusion-derived junction-spanning neoantigens [45].”
BackgroundKim, Y., Sidney, J., Buus, S., Sette, A., Nielsen, M., & Peters, B. (2014) · BMC Bioinformatics · doi:10.1186/1471-2105-15-241 · Cited by 83
Exploiting non-canonical translation to identify new targets for T cell-based cancer immunotherapy
Laumont, C. M., & Perreault, C. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2628-4 · Cited by 82 · cited 1×
“Noncoding transcripts can be created from noncoding exons, introns, and untranslated regions (UTRs), as well as from non-canonical reading frames in the coding region [53].”
BackgroundUltrasensitive detection of TCR hypervariable-region sequences in solid-tissue RNA–seq data
Li, B., Li, T., Wang, B., Dou, R., Pignon, J.-C., Choueiri, T. K., Signoretti, S., Liu, J. S., & Liu, X. S. (2017) · Nature Genetics · doi:10.1038/ng.3820 · Cited by 80 · cited 1×
“TCR repertoire profiling LymAnalyzer [194], MiXCR [147], MIGEC [148], pRESTO [195], TRUST [196], TraCeR [145], VDJtools [197], VDJviz [198], ImmunoSEQ [199], GLIPH [151]”
MethodMHCSeqNet: a deep neural network model for universal MHC binding prediction
Phloyphisut, P., Pornputtapong, N., Sriswasdi, S., & Chuangsuwanich, E. (2019) · BMC Bioinformatics · doi:10.1186/s12859-019-2892-4 · Cited by 77
Evaluation of computational programs to predict HLA genotypes from genomic sequencing data
Bauer, D. C., Zadoorian, A., Wilson, L. O. W., Melbourne Genomics Health Alliance, & Thorne, N. P. (2016) · Briefings in Bioinformatics · doi:10.1093/bib/bbw097 · Cited by 74
TSNAD: an integrated software for cancer somatic mutation and tumour-specific neoantigen detection
Zhou, Z. M., Lyu, X., Wu, J., Yang, X., Wu, S., Zhou, J., Gu, X., Su, Z., & Chen, S. (2017) · Royal Society Open Science · doi:10.1098/rsos.170050 · Cited by 74 · cited 1×
“Neoantigen prioritization pipelines pVACtools [8], Vaxrank [9], MuPeXI [119], TIminer [120], Neoepiscope [189], TSNAD [190], EpiToolKit [123], NeoepitopePred [122], TepiTool (IEDB) [191], ScanNeo [192], CloudNeo [193], NeoPredPipe [118]”
MethodShimmer: detection of genetic alterations in tumors using next-generation sequence data
Hansen, N. F., Gartner, J. J., Mei, L., Samuels, Y., & Mullikin, J. C. (2013) · Bioinformatics · doi:10.1093/bioinformatics/btt183 · Cited by 73 · cited 1×
“Variant callers SNV/Indel: Mutect [19], Strelka [20], VarScan2 [21], SomaticSniper [22], Shimmer [165], VarDict [166], deepSNV [167], EBCall [40] Structural variants: Pindel [43], Manta [168], Lumpy [169] Fusions: STAR-Fusion [48], Pizzly [47], SOAPfuse [170], JAFFA [49], ChimPipe [171], GFusion [50], INTEGRATE [51]”
BackgroundZhang, J., Caruso, F. P., Sa, J. K., Justesen, S. F. L., Nam, D., Sims, P. A., Ceccarelli, M., Lasorella, A., & Iavarone, A. (2019) · Communications Biology · doi:10.1038/s42003-019-0369-7 · Cited by 72 · cited 1×
“…analysis, the use of a consensus approach involving multiple tools has become a common strategy to increase confidence in HLA typing results [208] HLA typing (selection of data type and samples) Several options are available for input data when performing HLA typing from NGS data, including…”
MethodCloudNeo: a cloud pipeline for identifying patient-specific tumor neoantigens
Bais, P., Namburi, S., Gatti, D. M., Zhang, X., & Chuang, J. H. (2017) · Bioinformatics · doi:10.1093/bioinformatics/btx375 · Cited by 69 · cited 1×
“Neoantigen prioritization pipelines pVACtools [8], Vaxrank [9], MuPeXI [119], TIminer [120], Neoepiscope [189], TSNAD [190], EpiToolKit [123], NeoepitopePred [122], TepiTool (IEDB) [191], ScanNeo [192], CloudNeo [193], NeoPredPipe [118]”
MethodPHLAT: Inference of High-Resolution HLA Types from RNA and Whole Exome Sequencing
Bai, Y., Wang, D., & Fury, W. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8546-3_13 · Cited by 68 · cited 2×
“Although many class I typing algorithms exist, OptiType [69], Polysolver [70], and PHLAT [71] currently have the highest reported accuracies [67, 68, 70].”
BackgroundMethodGuo, Q., Wang, J., Xiao, J., Wang, L., Hu, X., Yu, W., Song, G., Lou, J., & Chen, J. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0875-0 · Cited by 66 · cited 2×
“Neoantigens contain altered amino-acid sequences that result from non-silent somatic mutations, whereas TAAs, which may originate from endogenous proteins or retroviruses, are selectively expressed or overexpressed by tumor cells but may also be expressed by non-tumor cell populations [13].”
BackgroundRosenberg, S. A., Tong-On, P., Li, Y., Riley, J. P., El‐Gamil, M., Parkhurst, M. R., & Robbins, P. F. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.168.5.2402 · Cited by 66
ScanNeo: identifying indel-derived neoantigens using RNA-Seq data
Wang, T.-Y., Wang, L., Alam, S. K., Hoeppner, L. H., & Yang, R. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz193 · Cited by 66 · cited 1×
“Neoantigen prioritization pipelines pVACtools [8], Vaxrank [9], MuPeXI [119], TIminer [120], Neoepiscope [189], TSNAD [190], EpiToolKit [123], NeoepitopePred [122], TepiTool (IEDB) [191], ScanNeo [192], CloudNeo [193], NeoPredPipe [118]”
MethodAccounting for proximal variants improves neoantigen prediction
Hundal, J., Kiwala, S., Feng, Y.-Y., Liu, C. J., Govindan, R., Chapman, W. C., Uppaluri, R., Swamidass, S. J., Griffith, O. L., Mardis, E. R., et al. (2018) · Nature Genetics · doi:10.1038/s41588-018-0283-9 · Cited by 64 · cited 2×
“…and expression of variant alleles); the phasing of variants (proximal variants detected on the same allele will influence neoantigen sequences) [32, 117]; the interpretation of variants in the context of clonality or heterogeneity [118]; the HLA expression and somatic mutations of patient tumors;…”
BackgroundSelf-citationExpression of antigen processing and presenting molecules in brain metastasis of breast cancer
Liu, Y., Komohara, Y., Domenick, N., Ohno, M., Ikeura, M., Hamilton, R. L., Horbinski, C., Wang, X., Ferrone, S., & Okada, H. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-011-1137-9 · Cited by 62 · cited 1×
“Downregulation of B2M , TAP1 , and TAP2 expression has also been shown to inhibit tumor antigen presentation [84, 85] and correlate with metastatic breast cancer phenotypes [86].”
BackgroundMaby, P., Galon, J., & Latouche, J.-B. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1115943 · Cited by 57
Kiyotani, K., Mai, T. H., & Nakamura, Y. (2016) · Journal of Human Genetics · doi:10.1038/jhg.2016.141 · Cited by 57 · cited 2×
“HLA class I typing algorithms (Table 1) have reached up to 99% prediction accuracy when compared to curated clinical typing results [67, 68].”
BackgroundTAPPred Prediction of TAP-Binding Peptides in Antigens
Bhasin, M., Lata, S., & Raghava, G. P. S. (2007) · Methods in molecular biology · doi:10.1007/978-1-60327-118-9_28 · Cited by 57 · cited 1×
“Different methods have been employed in an attempt to determine which peptides have high affinity for TAP binding, including simple/cascade support vector machine (SVM) models [93, 94] and weight matrix models [95].”
MethodAndreatta, M., Schafer‐Nielsen, C., Lund, O., Buus, S., & Nielsen, M. (2011) · PLoS ONE · doi:10.1371/journal.pone.0026781 · Cited by 54
Yu, Y., Ceredig, R. H., & Seoighe, C. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv1016 · Cited by 54 · cited 1×
“TCR repertoire profiling LymAnalyzer [194], MiXCR [147], MIGEC [148], pRESTO [195], TRUST [196], TraCeR [145], VDJtools [197], VDJviz [198], ImmunoSEQ [199], GLIPH [151]”
MethodCallari, M., Sammut, S., Mattos‐Arruda, L. D., Bruna, A., Rueda, O. M., Chin, S., & Caldas, C. (2017) · Genome Medicine · doi:10.1186/s13073-017-0425-1 · Cited by 53 · cited 1×
“For example, Callari et al. [25] achieved 17.1% higher sensitivity without increasing the false-positive rate by intersecting a single variant caller ’ s re-sults from multiple alignment pipelines and then combining the intersected results from two callers, MuTect2 and Strelka, to achieve a final…”
MethodInfluentialCalis, J. J. A., Reinink, P., Keller, C., Kloetzel, P. M., & Keşmir, C. (2014) · Immunogenetics · doi:10.1007/s00251-014-0815-0 · Cited by 53 · cited 3×
“0 Cterm has been shown to have the best performance in predicting in vivo proteolysis that provides peptide sources for MHC class I antigen presentation [88].”
BackgroundPaul, S., Karosiene, E., Dhanda, S. K., Jurtz, V., Edwards, L., Nielsen, M., Sette, A., & Peters, B. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01795 · Cited by 50 · cited 2×
“These tools include NetChop20S [89], NetChopCterm [89], and ProteaSMM [89, 90] for MHC class I antigens, and the more recent PepCleaveCD4 and MHC NP II for MHC class II antigens [91, 92].”
BackgroundMethodPeptide Delivery Systems for Cancer Vaccines
He, X., Abrams, S. I., & Lovell, J. F. (2018) · Advanced Therapeutics · doi:10.1002/adtp.201800060 · Cited by 48 · cited 1×
“Cancer vaccine delivery is an extensive topic beyond the scope of this review, but other reviews discuss this topic in detail [126 – 128].”
BackgroundB-cell lymphomas present immunoglobulin neoantigens
Khodadoust, M. S., Olsson, N., Chen, B., Sworder, B. J., Shree, T., Liu, C. L., Zhang, L., Czerwinski, D. K., Davis, M. M., Levy, R., et al. (2018) · Blood · doi:10.1182/blood-2018-06-845156 · Cited by 48 · cited 1×
“For example, V(D) J recombination and somatic hypermutation ge nerate immunoglobulin (Ig) variable region diversity in B and T lymphocytes, and the resulting unique receptor sequences can function as neoantigens in heme malignancies [37, 56].”
BackgroundFusion detection and quantification by pseudoalignmentPreprint
Melsted, P., Hateley, S. L., Joseph, I., Pimentel, H., Bray, N., & Pachter, L. S. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/166322 · Cited by 45 · cited 1×
“Many tools have been developed to predict fusion genes from RNA-seq and/or whole genome sequencing (WGS) data; recent tools include pizzly [47], STAR-fusion [48], JAFFA [49], GFusion [50], and INTEGRATE [51] (refer to Table 1).”
Attacking Tumors From All Sides: Personalized Multiplex Vaccines to Tackle Intratumor Heterogeneity
Fennemann, F. L., de Vries, I. J. M., Figdor, C. G., & Verdoes, M. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00824 · Cited by 44 · cited 1×
“In addition, tumors that exhibit high intratumoral heterogeneity can require alternative methods, such as collecting multiple biopsies per tumor [17].”
MethodChimPipe: accurate detection of fusion genes and transcription-induced chimeras from RNA-seq data
Rodríguez–Martín, B., Palumbo, E., Marco‐Sola, S., Griebel, T., Ribeca, P., Alonso, G., Rastrojo, A., Aguado, B., Guigó, R., & Djebali, S. (2017) · BMC Genomics · doi:10.1186/s12864-016-3404-9 · Cited by 43
Identification of candidate neoantigens produced by fusion transcripts in human osteosarcomas
Rathe, S. K., Popescu, F. E., Johnson, J. E., Watson, A. L., Marko, T. A., Moriarity, B. S., Ohlfest, J. R., & Largaespada, D. A. (2019) · Scientific Reports · doi:10.1038/s41598-018-36840-z · Cited by 43 · cited 1×
“Researchers recently investigated the presence of translocations in osteosarcoma, characterized by high genomic instability [44], and discovered multiple fusion-derived junction-spanning neoantigens [45].”
BackgroundBordner, A. J., & Mittelmann, H. D. (2010) · BMC Bioinformatics · doi:10.1186/1471-2105-11-482 · Cited by 42 · cited 1×
“2) [116], TEPITOPE [184], TEPITOPEpan [185], RANKPEP [186], MultiRTA [187], OWA-PSSM [188]”
EpiToolKit—a web-based workbench for vaccine design
Schubert, B., Brachvogel, H.-P., Jürges, C., & Kohlbacher, O. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btv116 · Cited by 41 · cited 2×
“Once the mutations are confirmed to exist and be expressed, the pipelines then generate a list of neoantigen candidates and consider the probability of cleavage, the location of cleavage, and the TAP transport efficiency of each candidate [8, 123, 124].”
BackgroundMethodVaxrank: A computational tool for designing personalized cancer vaccinesPreprint
Rubinsteyn, A., Hodes, I., Kodysh, J., & Hammerbacher, J. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/142919 · Cited by 41 · cited 3×
“Vaxrank [9] aims to address these concerns by incorporating a manufacturability prediction step in the neoantigen prioritization pipeline.”
BackgroundMethodInfluentialMorin, A., Kwan, T., Ge, B., Létourneau, L., Ban, M., Tandre, K., Caron, M., Sandling, J. K., Carlsson, J., Bourque, G., et al. (2016) · BMC Medical Genomics · doi:10.1186/s12920-016-0220-7 · Cited by 39 · cited 1×
“TCR repertoire profiling LymAnalyzer [194], MiXCR [147], MIGEC [148], pRESTO [195], TRUST [196], TraCeR [145], VDJtools [197], VDJviz [198], ImmunoSEQ [199], GLIPH [151]”
Development of an adenovirus vector vaccine platform for targeting dendritic cells
Sharma, P. K., Dmitriev, I. P., Kashentseva, E. A., Raes, G., Li, L., Kim, S. W., Lu, Z.-H., Arbeit, J. M., Fleming, T. P., Kaliberov, S. A., et al. (2017) · Cancer Gene Therapy · doi:10.1038/s41417-017-0002-1 · Cited by 38 · cited 1×
“To design a successful delivery vector, additional analysis steps are necessary to assess peptide manufacturability and to avoid potential incidental DNA vector junctional epitope sequences, or junctions spanning neoantigen sequences that create unintended immunogenic epitopes [8, 129].”
BackgroundSelf-citationEvaluation of machine learning methods to predict peptide binding to MHC Class I proteinsPreprint
Bhattacharya, R., Sivakumar, A., Tokheim, C. J., Guthrie, V. B., Anagnostou, V., Velculescu, V. E., & Karchin, R. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/154757 · Cited by 37
neoepiscope improves neoepitope prediction with multivariant phasing
Wood, M. A., Nguyen, A., Struck, A. J., Ellrott, K., Nellore, A., & Thompson, R. F. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz653 · Cited by 37
VDJviz: a versatile browser for immunogenomics data
Bagaev, D. V., Zvyagin, I. V., Putintseva, E. V., Izraelson, M., Britanova, O. V., Chudakov, D. M., & Shugay, M. (2016) · BMC Genomics · doi:10.1186/s12864-016-2799-7 · Cited by 37 · cited 1×
“TCR repertoire profiling LymAnalyzer [194], MiXCR [147], MIGEC [148], pRESTO [195], TRUST [196], TraCeR [145], VDJtools [197], VDJviz [198], ImmunoSEQ [199], GLIPH [151]”
MethodAGFusion: annotate and visualize gene fusionsPreprint
Murphy, C., & Elemento, O. (2016) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/080903 · Cited by 36 · cited 1×
“com/Ensembl/ensembl-vep) (SNV/Indel), AGFusion [172] (RNA fusions), bam-readcount (https://github.”
Cited by
Neoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020
Wells, D. K., van Buuren, M. M., Dang, K. K., Hubbard-Lucey, V. M., Sheehan, K. C. F., Campbell, K. M., Lamb, A., Ward, J. P., Sidney, J., Blazquez, A. B., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.015 · Cited by 538
Self-citationNeoantigen: A New Breakthrough in Tumor Immunotherapy
Zhang, Z., Lu, M., Qin, Y., Gao, W., Tao, L., Su, W., & Zhong, J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.672356 · Cited by 284
Neoantigen-targeted CD8+ T cell responses with PD-1 blockade therapy
Puig-Saus, C., Sennino, B., Peng, S., Wang, C. L., Pan, Z., Yuen, B., Purandare, B., An, D., Quach, B. B., Nguyen, D., et al. (2023) · Nature · doi:10.1038/s41586-023-05787-1 · Cited by 190
Self-citationRNA Dysregulation: An Expanding Source of Cancer Immunotherapy Targets
Pan, Y., Kadash-Edmondson, K. E., Wang, R., Phillips, J., Liu, S., Ribas, A., Aplenc, R., Witte, O. N., & Xing, Y. (2021) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2021.01.006 · Cited by 53
Metadata
- Authors
- Richters, M. M., Xia, H., Campbell, K. M., Gillanders, W. E., Griffith, O. L., & Griffith, M.
- Venue
- Genome Medicine
- Published
- 2019-08-28
- Volume
- 11
- Issue
- 1
- Pages
- 56-56
- ISSN
- 1756-994X (ISSN-L)
- OpenAlex
- W2971041153
- Cited by
- 214
- References
- 207
- FWCI
- 6.95
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.